Video
Dr. Leslie Discusses CAR T-Cell Therapy in MCL
Author(s):
Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses the developing role of chimeric antigen receptor (CAR) T-cell therapy for patients with mantle cell lymphoma (MCL).
Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses the developing role of chimeric antigen receptor (CAR) T-cell therapy for patients with mantle cell lymphoma (MCL).
CAR T-cell therapy is an exciting advancement across lymphoma subtypes, with recently approved constructs in the diffuse large B-cell lymphoma subtype (DLBCL), says Leslie. There are ongoing trials in MCL that show promising efficacy in heavily pretreated patients.
In terms of patients with indolent lymphoma, CAR T-cell therapy is interesting because patients get too sick before they are able to receive the infusion of cells. Although the data are limited, there are excellent results, and patients can stay well enough to receive treatment. Hopefully this can be a curative treatment for this group of patients, Leslie adds.
